Immune Pharmaceuticals Provides a Pipeline Update
May 23, 2018 08:00 ET
|
Immune Pharmaceuticals, Inc.
ENGLEWOOD CLIFFS, N.J., May 23, 2018 (GLOBE NEWSWIRE) -- Immune Pharmaceuticals, Inc. (NASDAQ:IMNP) (“Immune” or the “Company”), a biopharmaceutical company developing novel therapeutic agents for...
Immune Pharmaceuticals Presents Updated Positive Results from Phase 2 Trial of Bertilimumab in Bullous Pemphigoid
May 15, 2018 09:00 ET
|
Immune Pharmaceuticals, Inc.
- Results from all subjects confirm excellent safety and tolerability and a large benefit across a variety of efficacy measures despite aggressive prednisone tapering - - Positive data support...
Immune Pharmaceuticals Provides Update on Plans for Oncology Subsidiary, Cytovia, Inc.
May 07, 2018 08:30 ET
|
Immune Pharmaceuticals, Inc.
ENGLEWOOD CLIFFS, New Jersey, May 07, 2018 (GLOBE NEWSWIRE) -- Immune Pharmaceuticals, Inc. (NASDAQ:IMNP) (“Immune” or the “Company”), a biopharmaceutical company developing novel therapeutic agents...